S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)

Genmab A/S Stock Price, News & Analysis (NASDAQ:GMAB)

$32.28
-0.08 (-0.25%)
(As of 12/8/2023 ET)
Compare
Today's Range
$32.16
$32.65
50-Day Range
$27.94
$35.44
52-Week Range
$27.74
$47.12
Volume
301,205 shs
Average Volume
570,086 shs
Market Capitalization
$21.33 billion
P/E Ratio
34.34
Dividend Yield
N/A
Price Target
$41.60

Genmab A/S MarketRank™ Stock Analysis

Analyst Rating
Hold
2.47 Rating Score
Upside/​Downside
28.9% Upside
$41.60 Price Target
Short Interest
Healthy
0.23% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.52mentions of Genmab A/S in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
2.52%
From $1.19 to $1.22 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.72 out of 5 stars

Medical Sector

83rd out of 954 stocks

Pharmaceutical Preparations Industry

15th out of 362 stocks


GMAB stock logo

About Genmab A/S Stock (NASDAQ:GMAB)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

GMAB Stock Price History

GMAB Stock News Headlines

Genmab A/S (NASDAQ:GMAB) Rating Increased to Buy at UBS Group
Genmab A/S (NASDAQ:GMAB) Given "Buy" Rating at HC Wainwright
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
9 Analysts Have This to Say About Genmab
Genmab A/S GMAB
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
GMAB Nov 2023 45.000 call
H.C. Wainwright Keeps Their Buy Rating on Genmab (GMAB)
Why Shares of Zai Lab Limited Were Jumping on Tuesday
Genmab Is Down To Attractive Levels
Analyst Expectations for Genmab's Future
Genmab (GMAB) Receives a Buy from Truist Financial
Genmab A/S: Genmab Updates 2023 Financial Guidance
12 Analysts Have This to Say About Genmab
See More Headlines
Receive GMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/28/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GMAB
Fax
N/A
Employees
1,660
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$41.60
High Stock Price Target
$54.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+29.1%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
15 Analysts

Profitability

Net Income
$781.91 million
Pretax Margin
32.55%

Debt

Sales & Book Value

Annual Sales
$17.02 billion
Cash Flow
$1.27 per share
Book Value
$5.89 per share

Miscellaneous

Free Float
650,501,000
Market Cap
$21.29 billion
Optionable
Not Optionable
Beta
1.01

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Jan G.J. van de Winkel Ph.D. (Age 62)
    Co-Founder, President & CEO
    Comp: $2.75M
  • Mr. Anthony Pagano (Age 45)
    Executive VP & CFO
    Comp: $1.02M
  • Mr. Anthony Mancini (Age 52)
    Executive VP & COO
    Comp: $1.11M
  • Mr. Martin Schultz (Age 47)
    Senior Director of Clinical Operations & Non-Independent Director
    Comp: $73.03k
  • Dr. Judith V. Klimovsky M.D. (Age 65)
    Executive VP & Chief Development Officer
    Comp: $1.15M
  • Dr. Tahamtan Ahmadi (Age 50)
    Executive VP, Chief Medical Officer & Head of Experimental Medicines
    Comp: $1.1M
  • Dr. Mijke Zachariasse Ph.D. (Age 49)
    Senior Director, Head of Antibody Research Materials & Non-Independent Director
    Comp: $146.05k
  • Mr. Takahiro Hamatani (Age 48)
    Senior Director of Finance Japan & Non-Independent Director
    Comp: $73.03k
  • Mr. Andrew Carlsen
    Senior Director, VP & Head of Investor Relations
  • Ms. Birgitte Stephensen M.Sc. (Age 62)
    Executive VP & Chief Legal Officer

Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Genmab A/S was last updated on Sunday, December 3, 2023 at 4:29 PM.

Pros

Here are some ways that investors could benefit from investing in Genmab A/S:

  • Genmab A/S has recently announced positive clinical trial results for its latest product, which has the potential to drive significant revenue growth.
  • The company has a strong pipeline of innovative drugs in development, which could lead to future blockbuster products and increased market share.
  • Genmab A/S has a solid financial position with a healthy balance sheet and strong cash flow, providing stability and potential for future investments and acquisitions.
  • The company has a track record of successful collaborations with major pharmaceutical companies, which could lead to additional partnership opportunities and revenue streams.
  • Genmab A/S has a strong management team with extensive experience in the biopharmaceutical industry, providing confidence in the company's ability to execute its strategic plans.

Cons

Investors should be bearish about investing in Genmab A/S for these reasons:

  • The stock price of Genmab A/S has experienced significant volatility in recent periods, which may indicate higher risk and uncertainty for investors.
  • The biopharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact the company's ability to bring new products to market and generate revenue.
  • Genmab A/S relies heavily on the success of its pipeline products, and any setbacks or failures in clinical trials could have a negative impact on the company's financial performance.
  • The company operates in a global market, and changes in international trade policies or geopolitical tensions could affect its operations and financial results.
  • Investing in biopharmaceutical companies carries inherent risks, including the potential for regulatory delays, patent expirations, and competition from generic drugs.














GMAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Genmab A/S stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares.
View GMAB analyst ratings
or view top-rated stocks.

What is Genmab A/S's stock price target for 2024?

15 brokers have issued 12-month target prices for Genmab A/S's stock. Their GMAB share price targets range from $23.00 to $54.00. On average, they expect the company's share price to reach $41.60 in the next year. This suggests a possible upside of 28.9% from the stock's current price.
View analysts price targets for GMAB
or view top-rated stocks among Wall Street analysts.

How have GMAB shares performed in 2023?

Genmab A/S's stock was trading at $42.38 at the start of the year. Since then, GMAB shares have decreased by 23.8% and is now trading at $32.28.
View the best growth stocks for 2023 here
.

Are investors shorting Genmab A/S?

Genmab A/S saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 1,530,000 shares, a decrease of 15.9% from the October 31st total of 1,820,000 shares. Based on an average trading volume of 785,500 shares, the short-interest ratio is currently 1.9 days.
View Genmab A/S's Short Interest
.

When is Genmab A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our GMAB earnings forecast
.

How were Genmab A/S's earnings last quarter?

Genmab A/S (NASDAQ:GMAB) released its quarterly earnings results on Tuesday, November, 7th. The company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.34 by $0.13. Genmab A/S had a trailing twelve-month return on equity of 15.03% and a net margin of 25.54%.

What other stocks do shareholders of Genmab A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO).

When did Genmab A/S IPO?

(GMAB) raised $503 million in an initial public offering on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

Who are Genmab A/S's major shareholders?

Genmab A/S's stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (0.37%), Morgan Stanley (0.17%), Envestnet Asset Management Inc. (0.14%), Royal Bank of Canada (0.13%), Stifel Financial Corp (0.11%) and Hardman Johnston Global Advisors LLC (0.09%).

How do I buy shares of Genmab A/S?

Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GMAB) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -